What kind of patients with castration-naïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis
Authors:
- 1 December 2018
- journal article
- review article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 36 (12) , 505-517
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (NSFC 81672547, 81402110)
- Science and Technology Support Program of Sichuan Province (2015SZ0230-3)
This publication has 26 references indexed in Scilit:
- Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!European Urology, 2018
- Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysisEuropean Journal of Cancer, 2017
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate CancerNew England Journal of Medicine, 2017
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNew England Journal of Medicine, 2017
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialThe Lancet, 2016
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerNew England Journal of Medicine, 2015
- Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trialThe Lancet Oncology, 2015
- No improvement noted in overall or cause‐specific survival for men presenting with metastatic prostate cancer over a 20‐year periodCancer, 2013
- Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2013
- Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346)Journal of Urology, 2012